Inhibition of rotavirus infection in vitro and in vivo by a synthetic peptide from VP4
A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232–255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz et al. (J. Virol. 1991, 65, 3106–3113). Pretreatment of MA-104 cells with...
Saved in:
Published in | Vaccine Vol. 16; no. 9; pp. 916 - 920 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ltd
01.05.1998
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A synthetic peptide corresponding to bovine rotavirus C486 (BRV) VP4 amino acid sequence 232–255 (VP4-peptide) was studied with the objective of defining the origin of the protective immune response reported previously by Ijaz
et al. (J. Virol. 1991,
65, 3106–3113). Pretreatment of MA-104 cells with the VP4-peptide before infection with rotavirus prevented both the attachment of
35S-labelled virus and plaque formation
in vitro. In vivo studies using a murine rotavirus model demonstrated that intragastric administration of VP4-peptide protected subjects from challenge with virulent rotavirus. These results clearly indicate the importance of this epitope in virus-cell interactions and their potential as a rotavirus vaccine candidate. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/S0264-410X(97)00298-3 |